Journal of Clinical Oncology
Articles in this Issue
A novel endoscopic sleeve en bloc resection for sinonasal mucosal melanoma: A propensity score–matched comparison with conventional endoscopic surgery.
e18150 Background: Sinonasal mucosal melanoma (SNMM) is a rare and aggressive malignancy for which complete surgical excis...
Azeliragon, a RAGE inhibitor, plus temozolomide and radiotherapy in patients with newly diagnosed glioblastoma: Final results from a dose-finding phase in the CAN-201 NDG trial.
2015 Background: Radiotherapy (RT) plus temozolomide (TMZ) is the standard of care for patients (pts) with newly diagnosed...
Baseline visceral disease burden and treatment delivery factors association with outcomes after tumor-infiltrating lymphocyte therapy for metastatic melanoma.
e21521 Background: Outcomes following tumor-infiltrating lymphocyte (TIL) therapy vary in real-world practice, and accessi...
A randomized phase III study of pembrolizumab versus pembrolizumab with carboplatin plus pemetrexed for locally advanced or metastatic nonsquamous non–small cell lung cancer with PD-L1 TPS ≥ 50%: LAPLACE-50.
8554 Background: For patients with advanced non-squamous non-small cell lung cancer (NSCLC) and high PD-L1 expression (TPS...
Platinum chemotherapy and oncolytic virotherapy as used to cooperatively sustain stem-like CD8⁺ T-cell immunity via type I interferon modulation.
e14545 Background: Durable antitumor immunity depends on the maintenance of stem-like CD8⁺ T cells capable of sustaining l...
Indole alkaloid corynan isolated from <i>Petasites hybridus</i> as a potential antitumor agent.
e15158 Background: The aim of this study was to evaluate the antitumor activity of the alkaloid corynan, which we obtained...
Prior CTLA-4 blockade as associated with a hyperactive immunosuppressive signature and limited response to subsequent immunotherapy in melanoma.
2634 Background: Checkpoint blockade achieves durable long term responses in about 30-50% of patients with malignant melan...
DART (NCI/SWOG S1609): Comprehensive results from dual checkpoint inhibition with CTLA-4 and PD-1 blockade in rare cancers.
2502 Background: Rare tumors are underrepresented in clinical trials, though they collectively comprise an estimated 22% o...
Vitamin D insufficiency and risk of taxane-induced peripheral neuropathy: Results from SWOG S1714.
12012 Background: Taxane-induced peripheral neuropathy (TIPN) affects up to 70% of patients treated with taxanes and can l...
Efficacy of fruquintinib (F) plus sintilimab (S) versus axitinib (A) or everolimus (E) by scores of IMDC risk factors and PD-L1 expression at baseline in previously treated advanced renal cell carcinoma (RCC): A subgroup analysis of the FRUSICA-2 study.
4531 Background: FRUSICA-2 (NCT05522231), a randomized, open-label, controlled phase 2/3 study, demonstrated a significant...
Chemotherapy over surgery: The dominant prognosticator in synchronous pancreatic cancer with liver metastases—A multi-center propensity score–matched analysis.
e16403 Background: Patients with pancreatic ductal adenocarcinoma (PDAC) liver metastases have a poor prognosis, and the b...
Patient experiences with UGN-102 for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC): Insights for shared decision making.
4602 Background: Recurrent LG-IR-NMIBC can be managed using various approaches, including repeat transurethral resection o...
Real-world survival outcomes and prognostic factors with adjuvant pembrolizumab for renal cell carcinoma.
e16555 Background: The KEYNOTE-564 trial established adjuvant pembrolizumab as a standard of care for high-risk renal cell...
Cell-based second-generation immunotherapy BC1 in metastatic breast cancer.
e13083 Background: BC1 (BC-OTS-001; BriaCell Inc) is an allogeneic cancer cell line derived from invasive ductal carcinoma...
Expert perspectives in the management of myelofibrosis (MF): A survey of 20 US-based specialists.
e18590 Background: Management of MF has faced a wide variety of clinical challenges. Allogeneic stem cell transplantation...
Scaling prior authorization for philanthropic funding with artificial intelligence (AI): Five-year outcomes from Indian Cancer Society Cancer Cure Fund (ICS-CCF) NavyaAI implementation.
1610 Background: Indian Cancer Society - Cancer Cure Fund (ICS-CCF) is one of the largest charitable program for directly...
Association of Klotho protein with the risk of late complications in cancer survivors.
e24128 Background: Chemotherapy (CT) may cause late toxicities and accelerate aging. Klotho (Kl) is a protein involved in...
Ablation plus immunotherapy in advanced NSCLC patients who develop oligo-residual disease after anti–PD-1/L1 therapy: Updated results from the BOOSTER trial.
8563 Background: Local consolidative therapy (LCT) has been demonstrated to augment the survival benefits of immunotherapy...
ProTACT: A first-in-human, phase 1 dose escalation and expansion study evaluating the safety, tolerability, and anti-tumor activity of [ <sup>225</sup> Ac]Ac-FL-020, a PSMA-targeted radioconjugate, in patients with mCRPC.
TPS5141 Background: Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy is an emerging treatment modali...
Dynamic disease trajectories, not treatment timing, as a driver of outcomes in intrahepatic cholangiocarcinoma: A machine learning analysis.
e16018 Background: Intrahepatic cholangiocarcinoma (iCCA) exhibits marked heterogeneity in outcomes that is incompletely e...
Association of GLP-1 receptor agonist therapy with BCG response in high-risk non–muscle invasive bladder cancer.
4620 Background: Observational studies suggest glucagon-like peptide-1 receptor agonists (GLP-1RAs) are associated with re...
Clinical validation of a comprehensive genomic profiling–based approach for homologous recombination deficiency assessment.
e15087 Background: Homologous recombination deficiency (HRD) is a clinically actionable genomic biomarker in ovarian cance...
Real-world effectiveness of CDK4/6 inhibitor re-treatment in HR+/HER2- metastatic breast cancer.
e13039 Background: The postMONARCH trial showed modest progression-free survival (PFS) improvement with abemaciclib after...
Prognostic utility of baseline hypoalbuminemia vs. peripheral immune biomarkers in a real-world immunotherapy cohort.
e23413 Background: Peripheral immune biomarkers absolute lymphocyte count (ALC), Neutrophil-to-Lymphocyte ratio (NLR) are...
A multi-institutional, randomized, phase III trial comparing anatomical segmentectomy and lobectomy for clinical stage IA3 pure-solid non–small-cell lung cancer: West Japan Oncology Group study WJOG16923L (STEP UP trial).
TPS8123 Background: Recent pivotal clinical trials, conducted by the Japan Clinical Oncology Group and West Japan Oncology...